Latest News
- Min. Nadda Unveils ?13,000-Crore Bio-Pharma SHAKTI and Chemical Parks Push to Expand India’s Global Chemicals and Biologics Footprint
- Aurobindo Pharma Subsidiary Launches Generic Cancer Drug in US, Expands Oncology Portfolio in Global Generics Market
- KIMS Hospitals Introduces Adaptive Deep Brain Stimulation in India for Advanced Parkinson’s Treatment
Brecht Vanneste Takes Charge as Managing Director of MSD India
Experienced biopharma leader to spearhead growth and strategic expansion from Mumbai.
MSD, the multinational biopharmaceutical company also known as Merck & Co. outside the United States and Canada, has appointed Brecht Vanneste as the new Managing Director for its India operations. The leadership transition will become effective from March 1, 2026, with Vanneste set to be based in Mumbai as he assumes responsibility for guiding the company’s business strategy and market expansion in India.
Vanneste brings more than 27 years of experience with MSD across global markets, including leadership roles in oncology and broader commercial functions. Before his India assignment, he led the company’s oncology business unit in China, driving product introductions and portfolio development in that key market. Prior to that, he served as Managing Director for MSD in Belgium and Luxembourg, where he strengthened the company’s presence in oncology and other therapeutic areas.
Throughout his career at MSD, Vanneste has held senior roles in sales, marketing, access, and regional strategy, demonstrating extensive experience across multiple therapeutic segments and markets. His professional journey has taken him through critical leadership positions in Europe and Asia, reflecting his ability to lead diverse teams and grow complex pharmaceutical portfolios.
MSD’s appointment of Vanneste comes at a time when the Indian biopharmaceutical market is rapidly expanding, driven by rising demand for innovative medicines, vaccines, and specialty therapies. As Managing Director, Vanneste will be responsible for aligning MSD’s offerings with evolving healthcare needs in India, strengthening collaborations with healthcare stakeholders, and expanding the company’s footprint across key disease areas.
Industry observers say this leadership change underscores MSD’s commitment to reinforcing its strategic priorities in India, where the company continues to invest in research, market access, and patient-centric programs. Vanneste’s global experience is expected to support MSD’s ambitions to deepen local engagement and drive long-term growth across both established and emerging therapeutic categories.